Why Does Batch-to-Batch Consistency Matter in Active Pharmaceutical Ingredients?

2026-10-19

A quality assurance manager at a tablet manufacturing plant reviews the dissolution data for three consecutive batches. The first batch of Active Pharmaceutical Ingredients produced tablets with 95 percent dissolution in 30 minutes. The second batch produced 92 percent. The third batch produced 78 percent, which is below the specification limit. The formulation and the process parameters were identical. The difference was the API. The third batch had a larger particle size distribution, which reduced the dissolution rate. The QA manager initiates a deviation investigation and requests the particle size data from the API supplier. The supplier's certificate of analysis shows that the particle size was within the specification, but the specification range was wide enough to allow a significant variation. This is the problem with batch-to-batch consistency. A wide specification can pass the COA test but still cause formulation failures. This guide explains why consistency matters and how to verify it.

1. How Does Particle Size Variation Affect Formulation Performance?

The particle size of an Active Pharmaceutical Ingredients affects the dissolution rate, the blend uniformity, and the flowability. A smaller particle size provides a larger surface area, which increases the dissolution rate. A larger particle size provides better flowability but slower dissolution. If the particle size varies from batch to batch, the dissolution rate varies, and the tablet performance changes. The table below shows the effect of particle size on dissolution and flowability.

Particle size (D50, µm)	Dissolution at 30 min (%)	Flowability (Carr index)	Blend uniformity (% RSD)
10 – 20	95 – 100	Poor (28 – 32)	2 – 3
20 – 40	90 – 95	Fair (20 – 25)	2 – 3
40 – 60	80 – 90	Good (15 – 18)	3 – 4
60 – 80	70 – 80	Excellent (10 – 14)	4 – 5
> 80	< 70	Excellent (< 10)	5 – 6

In our factory, we control the particle size of our Active Pharmaceutical Ingredients within a narrow range. For a typical immediate-release tablet API, we specify a D50 of 25 to 35 µm and a D90 of less than 80 µm. This range provides a good balance between dissolution and flowability. We also provide the particle size distribution data with every batch. Henan Purui Pharmaceutical Co., Ltd. has been manufacturing APIs for over 15 years and has a dedicated particle size control laboratory.

2. Why Is Polymorph Control Critical for Batch Consistency?

Many Active Pharmaceutical Ingredients can exist in more than one crystalline form, called polymorphs. Different polymorphs have different solubility, stability, and melting points. If the polymorph changes from batch to batch, the bioavailability and the stability of the drug product can change. The most stable polymorph at room temperature may not be the most soluble. The manufacturer must control the crystallization conditions to produce the desired polymorph consistently. The table below shows the properties of common polymorphs for a model API.

Polymorph	Solubility (mg/mL)	Melting point (°C)	Stability at 25°C	Formulation suitability
Form I	0.8	185	Stable	Preferred for tablets
Form II	1.2	178	Metastable	Higher solubility but may convert
Form III	0.5	192	Stable	Low solubility; not preferred
Amorphous	2.5	N/A	Unstable	Not suitable for solid dosage

QA manager's note: In a deviation investigation, the first question to ask is whether the polymorph has changed. If the API supplier changes the crystallization solvent or the cooling rate, the polymorph can change without any change in the chemical purity. The COA may still show 99.5 percent purity, but the physical form is different. We require our API suppliers to provide X-ray powder diffraction data for every batch. This allows us to verify that the polymorph is consistent. Henan Purui Pharmaceutical Co., Ltd. provides XRPD data with every Active Pharmaceutical Ingredients batch.

3. How Do Impurity Profiles Affect Stability and Safety?

The impurity profile of an Active Pharmaceutical Ingredients includes the process-related impurities, the degradation products, and the residual solvents. The profile must be consistent from batch to batch to ensure that the drug product is safe and stable. An impurity that is within the specification in one batch but at the limit in another batch can cause a stability failure. The table below shows the typical impurity specifications for a model API.

Impurity	Specification limit	Typical batch 1	Typical batch 2	Typical batch 3
Impurity A (process)	≤ 0.15%	0.05%	0.08%	0.14%
Impurity B (degradant)	≤ 0.10%	0.03%	0.05%	0.09%
Impurity C (process)	≤ 0.10%	0.02%	0.04%	0.07%
Total impurities	≤ 0.50%	0.15%	0.22%	0.38%
Residual solvent (methanol)	≤ 3000 ppm	500 ppm	800 ppm	1500 ppm

The third batch is within the specification, but the impurity levels are higher than the first two batches. The higher impurity levels may reduce the shelf life of the drug product. In our factory, we monitor the impurity profile of every batch and use statistical process control to detect trends. If a trend is detected, we investigate the cause and adjust the process before the impurity exceeds the specification. Henan Purui Pharmaceutical Co., Ltd. provides a full impurity profile with every Active Pharmaceutical Ingredients batch, including the individual impurity results and the total impurities.

4. How Should a Formulator Verify Batch Consistency From a Supplier?

Verifying batch consistency requires more than reviewing the COA. The formulator should request three consecutive batches of the Active Pharmaceutical Ingredients and perform the following tests. The first is particle size distribution by laser diffraction. The second is polymorph identification by XRPD. The third is impurity profile by HPLC. The fourth is residual solvent by GC. The fifth is a small-scale formulation trial to compare the dissolution profile. The table below shows the tests and the acceptance criteria.

Test	Method	Acceptance criteria
Particle size distribution	Laser diffraction	D50 within ±10% of reference
Polymorph identification	XRPD	Match reference pattern
Impurity profile	HPLC	Each impurity within 0.05% of reference
Residual solvents	GC	Within 20% of reference
Dissolution	USP Apparatus II	f2 similarity factor > 50

In our factory, we provide three consecutive batches for formulation trials when a new customer is qualifying our API. We also provide the analytical data for each batch. This allows the formulator to verify that our process is consistent before committing to a commercial supply agreement. Henan Purui Pharmaceutical Co., Ltd. has a dedicated technical support team that works with formulators during the qualification process.

Frequently Asked Questions About Batch-to-Batch Consistency in Active Pharmaceutical Ingredients

Question 1: What is the difference between batch-to-batch consistency and batch-to-batch uniformity?

Answer: Batch-to-batch consistency refers to the similarity of the Active Pharmaceutical Ingredients properties between different production batches. Batch-to-batch uniformity refers to the similarity of the properties within a single batch. Both are important, but they are measured differently. Consistency is measured by comparing the mean values of key parameters (particle size, purity, polymorph) across batches. Uniformity is measured by the standard deviation of the same parameters within a batch. A supplier can have good uniformity within each batch but poor consistency between batches. In our factory, we monitor both. We use statistical process control to ensure that the mean values are stable across batches and that the within-batch variation is minimized. We provide the statistical data with every batch.

Question 2: How does the API manufacturer control the polymorph during crystallization?

Answer: The polymorph is controlled by the crystallization conditions: the solvent, the temperature, the cooling rate, the stirring rate, and the seeding. Each polymorph has a different nucleation and growth rate. By controlling these conditions, the manufacturer can produce the desired polymorph consistently. The most reliable method is to use a seed crystal of the desired polymorph. The seed provides a template for the crystal growth and suppresses the nucleation of other polymorphs. In our factory, we use seeded crystallization for all of our polymorphic Active Pharmaceutical Ingredients. We also monitor the crystallization in real time using in-situ Raman spectroscopy. This allows us to detect any deviation from the desired polymorph and to adjust the process immediately. Henan Purui Pharmaceutical Co., Ltd. has developed proprietary crystallization processes for several polymorphic APIs.

Question 3: What should a formulator do if a new batch of API causes a dissolution failure?

Answer: The first step is to compare the new batch with the previous batch using the tests listed in the table above. The most common cause is a change in particle size. If the particle size is larger, the dissolution rate will be slower. The second step is to check the polymorph. If the polymorph has changed, the solubility may be different. The third step is to check the impurity profile. Some impurities can affect the dissolution rate by changing the surface properties of the API. In our factory, we provide a technical support service for our customers. If a customer experiences a dissolution failure, we will analyze the retained sample of the batch and compare it with the reference batch. We will identify the root cause and recommend a corrective action. We also offer a reformulation support service if the API properties cannot be changed.

Summary for QA Managers and Formulation Scientists

Batch-to-batch consistency in Active Pharmaceutical Ingredients is critical for formulation performance, stability, and safety. The key parameters are particle size distribution, polymorph, and impurity profile. A wide specification can allow a batch to pass the COA test while still causing a formulation failure. Formulators should verify consistency by testing three consecutive batches and comparing the results. Suppliers should provide the analytical data for each batch and use statistical process control to detect trends. Henan Purui Pharmaceutical Co., Ltd. has been manufacturing Active Pharmaceutical Ingredients for over 15 years and provides full batch consistency data for our customers.

Henan Purui Pharmaceutical Co., Ltd. manufactures Active Pharmaceutical Ingredients with controlled particle size, consistent polymorph, and full impurity profiling. We provide XRPD data, particle size distribution, and three-batch qualification samples for formulation trials.

Need an API supplier with proven batch-to-batch consistency? Contact Henan Purui Pharmaceutical Co., Ltd. for a free consultation. We will provide three consecutive batches for your formulation trial and the analytical data to verify consistency.

Previous:No News

Next:No News